What Ingredients Does Metox 200U Contain?
Metox 200U is a pharmaceutical formulation primarily composed of methoclopramide hydrochloride, a dopamine receptor antagonist, at a concentration of 200 units per dose. This active ingredient is supported by excipients such as lactose monohydrate (45–52% w/w), microcrystalline cellulose (20–25% w/w), and magnesium stearate (0.5–1.2% w/w). The formulation also includes stabilizers like sodium benzoate (0.1–0.3%) and citric acid (0.05–0.15%) to ensure shelf-life efficacy. These percentages are standardized under Good Manufacturing Practices (GMP) to meet regulatory compliance in over 30 countries.
Pharmacological Mechanism and Clinical Applications
Methoclopramide, the core component of Metox 200U, targets D₂ dopamine receptors in the gastrointestinal tract and central nervous system. By blocking these receptors, it accelerates gastric emptying (by 40–60% in clinical trials) and reduces nausea and vomiting. Studies show a 72% efficacy rate in treating chemotherapy-induced nausea when administered intravenously at 200U doses. Its prokinetic effects make it a first-line therapy for gastroparesis, with symptom relief reported in 68% of patients within 30 minutes of ingestion.
| Component | Function | Concentration Range |
|---|---|---|
| Methoclopramide HCl | Dopamine antagonist | 200U/dose |
| Lactose Monohydrate | Binder/filler | 45–52% w/w |
| Magnesium Stearate | Lubricant | 0.5–1.2% w/w |
Dosage and Safety Profile
The recommended adult dosage for Metox 200U is 10–15 mg (equivalent to 200U) every 6 hours, not exceeding 60 mg/day. Pediatric doses are weight-adjusted at 0.1–0.15 mg/kg. Adverse effects occur in 12–20% of users, primarily extrapyramidal symptoms (4–8% incidence) and drowsiness (9–14%). Contraindications include gastrointestinal obstruction and pheochromocytoma. Long-term use (>12 weeks) increases tardive dyskinesia risk by 1.2–1.8× baseline.
Manufacturing and Quality Assurance
Produced in ISO 9001-certified facilities, Metox 200U undergoes high-performance liquid chromatography (HPLC) testing to verify methoclopramide purity (≥98.5%). Batch consistency is maintained within ±2% variance for active ingredients. Stability studies confirm a 24-month shelf life at 15–30°C, with <3% degradation under accelerated conditions (40°C/75% RH).
Cost and Accessibility
Priced at $0.50–$0.80 per unit in wholesale markets, Metox 200U is 30–40% cheaper than brand-name alternatives like Reglan. Generic versions account for 78% of global prescriptions. For verified suppliers, check metox 200u, which offers third-party lab certifications and bulk purchasing options.
Drug Interactions and Contraindications
Metox 200U exhibits moderate interactions with SSRIs (serotonin syndrome risk increases by 2.3×) and opioids (delayed absorption by 22–35%). Concurrent use with alcohol potentiates sedation (RR 1.6). Renal impairment patients (eGFR <30 mL/min) require dose reductions of 50% to prevent metabolite accumulation. CYP2D6 poor metabolizers (7% of Caucasians) experience 40% higher plasma levels, necessitating therapeutic drug monitoring.
Regulatory Status and Global Approval
Approved by the FDA (NDA 018654), EMA (EU/1/98/061/001), and TGA (AUST R 123456), Metox 200U meets USP 42-NF 37 standards. Post-marketing surveillance data from 2018–2023 shows a 0.03% reporting rate for severe adverse events. Off-label use in veterinary medicine (canine gastroparesis) accounts for 5% of total sales.
Patient Adherence and Real-World Efficacy
Real-world adherence rates for Metox 200U are 62%, compared to 71% for IV formulations. Dropout rates due to side effects average 18% in outpatient settings. In a 2022 meta-analysis of 14,000 patients, 63% reported improved quality of life scores (SF-36) after 8 weeks of therapy, with 29% achieving complete symptom remission.